pharma news today glp-1 obesity drug health drugs october 2025 Outlook for obesity in 2025: more Roche was among the first

Similarly, research using UK primary care databases has not identified an increased risk signal

While preclinical and clinical studies have reported anti-metabolic and anti-inflammatory benefits with a favourable safety profile, further evidence from long-term and large-scale trials is necessary to guide clinicians in real-life scenarios

Foods to avoid on semaglutide overlap significantly, with fried foods, carbonated beverages, and very spicy meals topping the list

10 Safety of Liraglutide: Pancreatitis has rarely been experienced by patients taking liraglutide (7 cases in phase II and III trials of 4,257 patients), prompting the close monitoring of the development of pancreatitis in patients prescribed liraglutide

Until now, Medicare beneficiaries have had to pay out of pocket for the obesity drugs, costing them potentially hundreds of dollars a month

Lewis, a Yale-trained board-certified dermatologist in private practice in New York City, also adds that the safety of using a GLP-1 should be determined based on nutritional status, including iron stores, protein stores, hormone recovery, and breastfeeding status